

PYC Therapeutics Announces Retirement of Dr. Bernard Hockings as Board Director

PERTH, Australia and NEW YORK, New York – March 26, 2021 – PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the retirement of Dr. Bernard Hockings from PYC's Board of Directors.

"Bernard has served on PYC's Board for more than 7 years and in that time has made tremendous contributions to the Company, including helping to lay the foundations for our evolution into a leading RNA therapeutics company. It has been a pleasure to work with Bernard previously as a fellow Board Director and more recently in my current capacity. Bernard leaves a lasting legacy at PYC and one on which we are excited to build," said Sahm Nasseri U.S. Chief Executive Officer of PYC Therapeutics. "Consistent with PYC's strategy of expanding our U.S. management team to enable access to U.S. capital markets, we look forward to appointing additional U.S. based and industry experienced Directors in the coming months."

"It has been a privilege to serve as a Board Director of PYC over the past years. I have had a lifelong interest in medical research and as such I am thrilled to see how PYC has evolved now into a Company on the cusp of translating exciting science into patient impact," said Dr. Hockings. "I am excited about the recent appointment of Dr. Rosenblatt as a Board Director and I know that PYC is well placed to deliver the full impact of its distinctive science going forward with a clear and focused strategy supported by a growing team and capabilities across both Australia and the U.S. I will be watching with excitement as PYC continues its transformation into a multi-asset, clinical-stage biotechnology company."

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC's discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorized for release by Sahm Nasseri, Director and incoming CEO of PYC in the U.S.

CONTACTS:

INVESTORS

Deborah Elson/Matthew DeYoung
Argot Partners
deborah@argotpartners.com
matthew@argotpartners.com

MEDIA

Leo Vartorella
Argot Partners
leo@argotpartners.com